For full details of each session, please view the event guide.
8:30 am
Morning Coffee
9:15 am Chair’s Opening Remarks
3D/Ex Vivo Models
9:30 am Improving the Safety Predictability of IO Modalities with Organ on Chip (OoC) Models
Synopsis
• Incorporating new OoC models in IO workflow: Key aspects to consider
• How to use OoC for Efficacy Models in IO
• Challenges in safety prediction in IO and how OoC can help
• High level overview of the regulatory status regarding using OoC based IO data in submission
10:00 am Round Table Discussions:
Synopsis
Discover multiple perspectives on the key issues in preclinical development. Join a roundtable discussion that
has been specifically designed to enable you to leave with insights that you can immediately implement into
your preclinical model strategies
Challenges in the scale-up and wider adoption of organoid models
How familiar should preclinical scientists be with Regulatory concepts? What should be considered in preclinical study design
Will isoform-specific detection and targeting in different tumour subtypes result into a further developed personalized Medicine?
10:45 am
Speed Networking & Morning Break
In Vitro Assays
11:45 am Session Reserved For Ocello
12:00 pm RNA-Sequencing Analysis of Immunotherapy Response in Organotypic Tumor Spheroids
Synopsis
• Bulk RNA-sequencing (RNA-seq) uncovers dynamic responses to interferon-gamma versus PD-1 blockade in murine organotypic spheroids
• Development of methods to extract cells and perform single cell RNAseq refines this analysis
• These high resolution ex vivo functional studies help to uncover novel immunobiology
12:30 pm RG OncoRat – An Immunodeficient Rat Model to Compliment Your Oncology Programme
Synopsis
• Novel immunodeficient rat model that demonstrates superior human tumor development efficiency and growth kinetics compared to similar mouse models
• Larger blood volume and tumor size allow for serial blood and core biopsy sampling for PK/PD analyses
• Potential for humanizing the immune system for immuno-oncology studies
12:45 pm
Networking Lunch
1:45 pm Panel Discussion: To What Extent Will Ex-Vivo Platform Replace In-Vivo Models From Technical, Ethical, and Regulatory Standpoints?
2:30 pm Improving Therapy and Stratification by Listening to Mitochondria
Synopsis
• If you want your drug to work in cancer, it has to kill the cancer cell
• Mitochondria decide whether or not the cancer cell dies via apoptosis
• BH3 profiling predicts whether apoptosis will occur
Supporting Techniques in Evaluating Therapeutic Response
3:00 pm Imaging of PD-L1 in Head and Neck Cancer in Response to Oncolytic Virotherapy
3:30 pm PK/PD from Drug Discovery to Registration: An Industry Case Study
Synopsis
– PK/PD is a key tool in drug discovery and development
– Pre-clinical PK/PD knowledge is continually informative through compound identification, dose projection, clinical study designs and drug registration
– Establishing efficacious concentrations early helps to design molecules with high potential
4:00 pm Chair’s Closing Remarks
4:15 pm End of Day 2
For full details of each session, please view the event guide.